You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?

  • Authors: Kathy Madden, FNP, AOCNP, APHN; Beth Eaby-Sandy, MSN, CRNP; Michelle Offner, MSN, ACNP-BC
  • CE Released: 11/24/2019
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 11/24/2020
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses, nurse practitioners, and other healthcare professionals who treat cancer patients with immune checkpoint inhibitors.

The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Factors, such as medications and a patient's medical history, that may influence the efficacy of ICIs in patients with cancer
  • Have greater competence related to
    • Optimizing communication between the cancer care team and the patient/caregiver related to irAEs, including reporting and identifying toxicities
    • Applying best nursing practices in the management of irAEs


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Kathy Madden, FNP, AOCNP, APHN

    Nurse Practitioner
    NYU Langone Perlmutter Cancer Center
    New York, New York

    Disclosures

    Disclosure: Kathy Madden, FNP, AOCNP, APHN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Merck & Co., Inc.

  • Beth Eaby-Sandy, MSN, CRNP

    Nurse Practitioner
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Beth Eaby-Sandy, MSN, CRNP, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Helsinn Therapeutics, Inc; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.

  • Michelle Offner, MSN, ACNP-BC

    Nurse Practitioner
    The Angeles Clinic and Research Institute
    Los Angeles, California

    Disclosures

    Disclosure: Michelle Offner, MSN, ACNP-BC, has disclosed no relevant financial relationships.

Steering Committee

  • Jeffrey S. Weber, MD, PhD

    Professor of Medicine
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York

    Disclosures

    Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; EMD Serono, Inc.; Genentech, Inc.; GlaxoSmithKline; Incyte Corporation; Merck & Co., Inc.; Pfizer Inc.
    Received grants for clinical research from: Mirati; NextCure
    Owns stock, stock options, or bonds from: Altor; Biond; CyToMx
    Other: Named on a patent for a PD-1 biomarker by Biodesix; named on a patent for a CTLA-4 biomarker by Moffitt

  • Robert L. Ferris, MD, PhD

    Professor and Chief
    Division of Head and Neck Surgery
    Departments of Otolaryngology, Radiation Oncology, and Immunology
    Co-Leader
    Cancer Immunology Program
    University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania

    Disclosures

    Disclosure: Robert L. Ferris, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Aduro Biotech, Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bain Capital Life Sciences; Bristol-Myers Squibb Company; EMD Serono, Inc.; GlaxoSmithKline; Iovance Biotherapeutics; Lilly; MacroGenics; MedImmune Inc.; Merck & Co., Inc.; Nanobiotix; Numab Therapeutics AG; Oncorus; Ono Pharmaceutical Co., Ltd.; Pfizer Inc.; PPD; Regeneron Pharmaceuticals, Inc.; TESARO, Inc.; Torque Therapeutics, Inc.; TTMS
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; MedImmune Inc.; Merck & Co., Inc.; TESARO, Inc.; TTMS; VentiRx Pharmaceuticals

  • Ramaswamy Govindan, MD

    Professor of Medicine
    Division of Medical Oncology
    Washington University School of Medicine
    Co-Director
    Section of Medical Oncology
    Siteman Cancer Center
    Barnes-Jewish Hospital
    St. Louis, Missouri

    Disclosures

    Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Achilles

  • Dung Le, MD

    Associate Professor
    Johns Hopkins University School of Medicine
    Baltimore, Maryland
    Participation by Dr Le does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Disclosures

    Disclosure: Dung Le, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck & Co., Inc.
    Served as a speaker or a member of a speakers bureau for: Merck & Co., Inc.
    Received grants for clinical research from: Aduro Biotech; Bristol-Myers Squibb Company; Merck & Co., Inc.

  • Brian I. Rini, MD

    Ingram Professor of Medicine
    Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee

    Disclosures

    Disclosure: Brian I. Rini, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AVEO Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc.; Roche; Surface Oncology
    Received grants for clinical research from: AVEO Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Peloton; Pfizer Inc.; Roche

  • Jared Weiss, MD

    Assistant Professor of Medicine
    Lineberger Comprehensive Cancer Center
    University of North Carolina at Chapel Hill

    Disclosures

    Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Azitra; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Genentech, Inc.; Inivata; Jounce; Pfizer Inc.
    Owns stock, stock options, or bonds from: Nektar

Editors

  • Charlotte Warren

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

  • Vandana Iyer, PhD

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Vandana Iyer, PhD, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

SITC Course Director

  • Lisa Kottschade APRN, MSN, CNP

    Nurse Practitioner- Melanoma/Cutaneous Oncology
    Associate Professor of Oncology
    Chief Operations Officer- Midwest Melanoma Partnership

    Disclosures

    Disclosure: Lisa Kottschade, APRN, MSN, CNP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company
    Received grants for clinical research from: Bristol-Myers Squibb Company

SITC

  • Mary Dean, JD, CAE

    Associate Executive Director
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Mary Dean, JD, CAE, has disclosed no relevant financial relationships.

  • Jacqueline Gearhart

    Program Manager
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Jacqueline Gearhart has disclosed no relevant financial relationships.

  • Claire Leischer, MS

    Senior Manager of Online Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.

  • Alicia Schuessler, CAE

    Director of Education
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships

  • Tara Withington, CAE

    Executive Director
    Society for Immunotherapy of Cancer
    Milwaukee, Wisconsin

    Disclosures

    Disclosure: Tara Withington, CAE, has disclosed no relevant financial relationships.

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and Society for Immunotherapy of Cancer.



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?

Authors: Kathy Madden, FNP, AOCNP, APHN; Beth Eaby-Sandy, MSN, CRNP; Michelle Offner, MSN, ACNP-BCFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 11/24/2019

Valid for credit through: 11/24/2020

processing....

Educational Impact Challenge

The goal of this activity is to increase understanding of the issues surrounding immune checkpoint inhibitors (ICIs), including the risk for immune-related adverse events (irAEs) and optimal patient/caregiver communication.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print